SRZN

Surrozen is a clinical-stage biotech, not an operating business you can value on fundamentals. The 10-K is explicit: net losses since 2015 inception, a $527.3M accumulated deficit, and management 'expect(s) to continue to incur losses for the foreseeable future' with 'substantial expenses' ahead for clinical trials and manufacturing. The reported $3.48M of FY2025 revenue (down 67.4%) is collaboration/licensing income (the Boehringer Ingelheim Fzd4 deal), not product sales — so the 82.3x P/S is meaningless except as a flag that price is untethered from any commercial reality. The strategic pivot to ophthalmology means the pipeline is early and pre-approval, so value hinges entirely on unknowable trial outcomes.

The balance sheet is the disqualifier. Stockholders' equity is negative $188M and liabilities jumped 310% to $286M, driving a negative liabilities/equity ratio. The $242M net loss dwarfs the $42.1M operating loss, meaning roughly $200M is non-operating — almost certainly a change in fair value of warrant/derivative liabilities, which also explains the liability explosion and the -$32.37 diluted EPS. That is a capital structure loaded with instruments that can dilute or overhang the equity, on top of shares outstanding already up 250% year-over-year. Retained earnings of -$527M confirm this company has only ever consumed capital.